IMPDH inhibitors for anti-tumor therapy in tuberous sclerosis complex
Alexander J. Valvezan(Rutgers, The State University of New Jersey), Brendan D. Manning(Cancer Research Center), Molly C. McNamara(Harvard University), Margaret E. Torrence(Harvard University), John M. Asara(Beth Israel Deaconess Medical Center), Elizabeth P. Henske(Brigham and Women's Hospital), Spencer K. Miller(Harvard University)
Cited by 4
Related Papers
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
|Nature Genetics|2011|1.1k
Vitamin C selectively kills <i>KRAS</i> and <i>BRAF</i> mutant colorectal cancer cells by targeting GAPDH
|Science|2015|907
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|860